Core Viewpoint - Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. maintains a stable credit rating of AA for both the company and its convertible bonds, reflecting its strong market position in heparin production and sales, despite facing challenges in raw material pricing and market fluctuations [1][3][4]. Company Overview - The company specializes in the research, production, and sales of a full range of heparin products, including heparin sodium raw materials and low molecular weight heparin preparations, along with anti-tumor preparations and other sterile injectables [7][12]. - As of the end of 2024, the company reported total assets of 95.10 billion yuan and total equity of 64.88 billion yuan, with an operating income of 39.24 billion yuan and a profit of 9.92 billion yuan [7][12]. Financial Performance - In 2024, the company achieved a total profit of 9.92 billion yuan, recovering from a loss in the previous year, with a gross profit margin of 43.28%, although this was a decline from 48.45% in 2023 [5][14]. - The company’s total debt decreased by 20.68% to 20.79 billion yuan by the end of 2024, with a cash-to-short-term debt ratio of 1.67, indicating strong liquidity [5][14]. Market Position and Industry Analysis - The global heparin market is projected to grow at a compound annual growth rate (CAGR) of 5% to 7%, driven by an aging population and increasing prevalence of cardiovascular diseases [11][12]. - The company holds a competitive advantage in research and development, with 49 ongoing projects and a research investment of 532 million yuan, accounting for 13.57% of total revenue in 2024 [4][5]. Risks and Challenges - The company faces risks related to raw material supply, currency fluctuations, and trade tensions, particularly with a significant portion of its revenue (76.75% in 2024) coming from overseas sales [4][6]. - The price of standard heparin raw materials has been on a downward trend, impacting the company's revenue from this segment, which decreased by 21.05% to 7.87 billion yuan in 2024 [14][19]. Future Outlook - The company is expected to enhance its competitive edge as it expands its formulation business and continues to launch new pharmaceutical products [3][11]. - The stable cash reserves and reduced debt burden suggest that the company’s ability to service its convertible bonds will remain strong, with potential for credit rating upgrades if overseas market expansion and capital strength improve significantly [3][4].

《 长中短周期动量的考察角度和量化 》 《 成交量（金额）加权以后的标准化强度 》 短期和长期强度排序，是每天复盘必做的功课。短期排序显示当下最强的热点中最强的股票，长期排序显示长期趋势中当下最强的股票。用指标排序功能 选择OVS指标，再附加一个SSV指标，就可以一次性完成对所有股票的排序。一般我只取前50只票。 以下是昨天用短期OVS排序得到的TOP50个股，今天集合竞价后的涨幅排名，准确捕捉到了昨天稳定币题材的几只票。下面还有创新药的几只票。 以下是昨天用长期SSV排序得到的TOP50个股，今天开盘之后的涨幅排名，几只最牛的创新药赫然在列。 | 1 | 300204 舒泰神 | | 140.88 | -17.39 | 69.49亿 医药医疗-生物制品 | 产品销售 | 13.54 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2 | 603390 通达电气 | | 95.15 | -22.80 | 24.73亿 汽车-汽车零部件 | 车载智能系统系列, | 10.02 | | 3 | 300368 汇金股份 | | 39.41 | -18.70 ...